country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-186196

Copy Link Print Information

Fentomycin-1

Fentomycin-1 is a ferroptosis inducer. Fentomycin-1 activates lysosomal iron²⁺ under acidic conditions with hydrogen peroxide to form a reactive iron-oxo species, which induces oxidative degradation, oxidation, and lipolysis of membrane phospholipids, triggering ferroptosis. Fentomycin-1 can be used for the research of pancreatic ductal adenocarcinoma, breast cancer metastasis, and melanoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 3095435-04-1
Formel: C₅₆H₆₆N₈O₆
Molecular Weight:947.17

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Fentomycin-1 Chemical Structure

CAS. Nr.: 3095435-04-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

Fentomycin-1 enhances iron-mediated oxidation of unsaturated phospholipids in a cell-free lysosome-like environment^[1].
Fentomycin-1 (1 μM; 1 h) localizes to the plasma membrane under low endocytic flux conditions and accumulates in the endolysosomal compartment of HT-1080 cells at physiological temperature^[1].
Fentomycin-1 (1-10 μM; 1-48 h) induces ferroptosis in HT-1080, primary PDAC, primary sarcoma, and 4T1 cells via membrane phospholipid oxidation^[1].
Fentomycin-1 (Sublethal doses; 48 h) induces HT-1080 cells to acquire a ferroptosis-resistant, epithelial-like cell state characterized by upregulated ferroptosis suppressors, lysosome-associated proteins, and lipid metabolism pathways, alongside downregulated mesenchymal markers and iron homeostasis proteins^[1].
Fentomycin-1 (5 μM; 72 h) eradicates Doxorubicin (HY-15142A)-induced drug-tolerant persister SUM159 triple-negative breast cancer cells in vitro^[1].
Fentomycin-1 (1 μM; 24 h) reduces the CD44^high subpopulation in primary human PDAC and UPS cells via ferroptosis^[1].
Fentomycin-1 specifically activates lysosomal iron to induce ferroptosis and selectively targets iron-rich CD44^high cancer cells^[2].
Fentomycin-1 increases FSP1 mRNA levels in HT-1080 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence^[1]

Cell Line:

HT-1080 fibrosarcoma cells
Concentration:

1 μM
Incubation Time:

1 h
Result:

Localized to the plasma membrane under low endocytic flux conditions.
Accumulated in the endolysosomal compartment, colocalizing with LysoTracker, at 37°C.
Showed stronger endolysosomal accumulation than untethered Chen-White ligand, which had weak pan-cellular staining.

Cell Viability Assay^[1]

Cell Line:

HT-1080 fibrosarcoma cells, human primary pancreatic ductal adenocarcinoma (PDAC) cells, human primary sarcoma cells, mouse 4T1 breast cancer cells
Concentration:

1 μM; 2 μM; 10 μM
Incubation Time:

1 h; 6 h; 24 h; 48 h
Result:

Induced oxidation of membrane phospholipids in HT-1080 cells to a greater extent than well-established ferroptosis inducers.
Reduced phospholipid oxidation levels when co-treated with α-tocopherol, deferiprone, and liproxstatin-1.
Reduced cell viability, with cell death antagonized by ferroptosis inhibitors but not by apoptosis or necroptosis inhibitors.
Left residual toxicity despite ferroptosis inhibitor treatment.
Increased levels of lysophospholipids and glycerol, indicating oxidized phospholipid degradation.

Cell Proliferation Assay^[1]

Cell Line:

Doxorubicin-induced drug-tolerant persister (DTP) SUM159 triple-negative breast cancer cells
Concentration:

5 μM
Incubation Time:

72 h
Result:

Eradicated doxorubicin-induced DTP SUM159 cells, significantly reducing the number of colonies formed compared to vehicle treatment.

In Vivo

Fentomycin-1 (0.003 mg per animal; intralymphatic; every other day) reduces intranodal tumour growth and increases tumour-size-based survival in a mouse model of triple-negative breast cancer metastasis by targeting CD44^high iron-rich cancer cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Balb/c (female, 6-8 weeks old, syngeneic 4T1 triple-negative breast cancer intranodal metastasis model)^[1]
Dosage:

0.003 mg per animal
Administration:

intralymphatic; every other day
Result:

Reduced intranodal tumour volume compared with vehicle control on day 10 post-treatment initiation.
Increased tumour-size-based survival, with a Mantel-Cox log-rank test P value of 8.7×10^-5 compared with vehicle.
Reduced abundance of CD44high cancer cells from 20.2% in vehicle-treated mice to 11.0% in treated mice.
Increased oxidation of membrane phospholipids in residual tumours.
Caused no adverse effects on body weight.

Chemical Information

CAS. Nr. 3095435-04-1
Molecular Weight 947.17
Formel C₅₆H₆₆N₈O₆
SMILES

O=C(C1=C(C2=C(C=C(C=C2)C)C=C1)C3=O)C4=C3C=CC5=C4N[C@@]6(C)C(OC(CCC(NCCCCNC7=CC=NC(CN8CCC[C@H]8[C@@H]9CCCN9CC%10=CC(N(C)C)=CC=N%10)=C7)=O)=O)[C@H](C)O[C@]5([H])C6
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Cañeque T, et al. Activation of lysosomal iron triggers ferroptosis in cancer. Nature. 2025;642(8067):492-500. [Content Brief]

[2]. Ali Boubacar K, et al. Regulation of ferroptosis by BAP1. Cell Death Differ. 2026 Jan 23. [Content Brief]

[3]. Palma M, et al. Lymph node environment drives FSP1 targetability in metastasizing melanoma. Nature. 2026;649(8096):477-486. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen